Ellingson, B. M., Aftab, D. T., Schwab, G. M., Hessel, C., Harris, R. J., Woodworth, D. C., Leu, K., Chakhoyan, A., Raymond, C., Drappatz, J., de Groot, J., Prados, M. D., Reardon, D. A., Schiff, D., Chamberlain, M., Mikkelsen, T., Desjardins, A., Holland, J., Ping, J., Weitzman, R., Wen, P. Y., & Cloughesy, T. F. (2018). volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro-oncology, 20(10), 1411–1418. http://access.bl.uk/ark:/81055/vdc_100095476192.0x00000e